A.S. Silantyev(1), I.V. Chekhonin(2), A.A. Chernysheva(2), O.I. Gurina(2), S.A. Pavlova(3), G.V. Pavlova(3, 4, 5), T.A. Savelieva(6, 7), V.B. Loshhenov(6, 7), V.P. Chekhonin(2, 8) 1-National Scientific Research Center on Addictions a branch of the V.P. Serbsky National Medical Research Centre for Psychiatry and Narcology, Maly Mogiltsevsky by-street, 3, Moscow, 119002, Russian Federation; 2V-.P. Serbsky National Medical Research Centre for Psychiatry and Narcology, Kropotkinskiy by-street, 23, Moscow, 119034, Russian Federation; 3-Institute of Gene Biology Russian Academy of Sciences, Vavilova Street, 34/5, Moscow, 119334, Russian Federation; 4-Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Trubetskaya Street, 8, Moscow, 119991, Russian Federation; 5-N.N. Burdenko National Medical Research Center of Neurosurgery, 4 Tverskaya-Yamskaya str., 16, Moscow, 125047, Russian Federation; 6-Prokhorov General Physics Institute, Vavilova str., 38, Moscow, 119991, Russian Federation; 7-National Research Nuclear University, Moscow Engineering Physics Institute, Kashirskoe Highway, 31, Moscow, 115409, Russian Federation; 8-Pirogov Russian National Research Medical University, Ostrovitianova str., 1, Moscow, 117997, Russian Federation E-mail: [email protected]

Introduction. Based on current literature data, it is possible to assume that when exposed to glioma cells astrocytes, may undergo a reactive transformation. These glioma-conditioned astrocytes might create a permissive environment for tumorigenesis. The aim of the study. To investigate the effects of glioma cells on astrocytes in co-culture. Methods. In terms of the current work, we conducted a pairwise comparison of protein levels between C6 glioma cells, native rat astrocytes, and glioma-conditioned rat astrocytes. The samples were prepared and analyzed with liquid chromatography–high-resolution mass spectrometry. Results. The analysis showed a significant difference in 162 proteins between glioma cells and native astrocytes, in 141 proteins between glioma cells and glioma-conditioned astrocytes and 70 proteins between glioma-conditioned and native astrocytes. Conclusion. The differences in protein levels between native and glioma-conditioned astrocytes show a high correlation with differences between glioma cells and native astrocytes.
reactive astrocytes, glioma C6, proteomics, mass spectrometry

Список литературы: 
  1. Charles N.A., Holland E.C., Gilbertson R., Glass R., Kettenmann H. The brain tumor microenvironment. Glia. 2012; 60 (3): 502–14.
  2. Zamanian J.L., Xu L., Foo L.C., Nouri N., Zhou L., Giffard R.G., Barres B.A. Genomic analysis of reactive astrogliosis. J. Neurosci. 2012; 32 (18): 6391–410.
  3. Placone A.L., Quinones-Hinojosa A., Searson P.C. The role of astrocytes in the progression of brain cancer: complicating the picture of the tumor microenvironment. Tumour Biol. 2015.
  4. Lu P., Wang Y., Liu X., Wang H., Zhang X., Wang K., Wang Q.,Hu R. Malignant gliomas induce and exploit astrocytic mesenchymal-like transition by activating canonical Wnt/beta-catenin signaling. Med Oncol. 2016; 33 (7): 66.
  5. Biasoli D., Sobrinho M.F., da Fonseca A.C., de Matos D.G., Romao L., de Moraes Maciel R., Rehen S.K., Moura-Neto V., Borges H.L.,Lima F.R. Glioblastoma cells inhibit astrocytic p53-expression favoring cancer malignancy. Oncogenesis. 2014; 3: 123.
  6. Baklaushev V.P., Yusubalieva G.M., Tsitrin E.B., Gurina O.I., Grinenko N.P., Victorov I.V.,Chekhonin V.P. Visualization of Connexin 43-positive cells of glioma and the periglioma zone by means of intravenously injected monoclonal antibodies. Drug Deliv. 2011; 18 (5): 331–7.
  7. Suk K. Proteomic analysis of glioma chemoresistance. Curr Neuropharmacol. 2012; 10 (1): 72–9.
  8. Deighton R.F., McGregor R., Kemp J., McCulloch J., Whittle I.R. Glioma pathophysiology: insights emerging from proteomics. Brain Pathol. 2010; 20 (4): 691–703.
  9. Koncarevic S., Urig S., Steiner K., Rahlfs S., Herold-Mende C., Sueltmann H., Becker K. Differential genomic and proteomic profiling of glioblastoma cells exposed to terpyridineplatinum (II) complexes. Free Radic Biol Med. 2009; 46 (8): 1096–108.
  10. Khalil A.A. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci. 2007; 98 (2): 201–13.
  11. Han M.Z., Xu R., Xu Y.Y., Zhang X., Ni S.L., Huang B., Chen A.J., Wei Y.Z., Wang S., Li W.J., Zhang Q., Li G., Li X.G., Wang J. TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas. J. Exp. Clin. Cancer Res. 2017; 36 (1): 155.
  12. Stifani S. The Multiple Roles of Peptidyl Prolyl Isomerases in Brain Cancer. Biomolecules. 2018; 8 (4).